Glutamate for Metabolic Intervention in Coronary Surgery (GLUTAMICS)
Coronary Artery Bypass, Myocardial Ischemia, Myocardial Infarction
About this trial
This is an interventional prevention trial for Coronary Artery Bypass focused on measuring Coronary Artery Bypass, Myocardial Protection, Angina, Unstable, Myocardial Ischemia, Myocardial Infarction, Unstable Coronary Artery Disease, Glutamate
Eligibility Criteria
Inclusion Criteria:
- surgery for unstable coronary artery disease (unstable angina, non-STEMI)
- accepted for surgery < 2 weeks after STEMI
- coronary surgery for indications above performed with or without cardiopulmonary bypass
- coronary surgery for indications above with or without simultaneous valve procedure
Exclusion Criteria:
- informed consent not possible because of critical condition or other reason
- preoperative use of inotropes or mechanical circulatory assist
- preoperative dialysis
- redo-procedure
- unexpected intraoperative finding / event that increased the dignity of the procedure to overshadow the originally planned operation
- body weight > 125 kg
- food allergy known to have caused flush, rash or asthma
Sites / Locations
- Blekingesjukhuset, Karlskrona
- University Hospital, Linköping
- University Hospital, Örebro
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Intravenous glutamate
Saline infusion
Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
Intravenous infusion of saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.